Organization
Institut für Klinische Krebsforschung
32 clinical trials
Clinical trial
A Phase II Study of Fedratinib and Nivolumab Combination in Patients With Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor TreatmentStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid TumorsStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing: a Non-randomized, Open-label, Single-arm Phase II StudyStatus: Recruiting, Estimated PCD: 2029-11-01
Clinical trial
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of LifeStatus: Recruiting, Estimated PCD: 2027-01-10
Clinical trial
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2024-02-01
Clinical trial
A Phase Ib/II Single-arm, Multicenter Study of Sacituzumab-govitecan, a TROP-2 Targeting Antibody Linked With SN38, for Patients With Metastatic Esophagogastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver FunctionStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage, cT1 and cT2N0, Esophageal Adenocarcinoma With Indication for Radical Surgery: A Prospective, Multicenter Study of the FLOT-AIO Gastric Cancer GroupStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOPStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase II Study of Immunotherapy With Durvalumab and Tremelimumab in Combination With Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner DesignStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase-II Open-label Study of Pembrolizumab and Lenvatinib in Patients With Advanced Stage Hepatocellular Carcinoma Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of Pemigatinib After Curative Local Therapy in Locally Advanced Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements.Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction - A Randomized Phase 2 Trial.Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Combined Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Metastatic or Inoperable Leiomyosarcoma - DiTuSarc StudyStatus: Recruiting, Estimated PCD: 2024-07-26
Clinical trial
The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Pembrolizumab and Trastuzumab in Combination With FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma - A Phase II Trial of the AIO Study Group - PHERFLOT -Status: Active (not recruiting), Estimated PCD: 2027-10-01
Clinical trial
IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage HepatocellularStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
A Phase II Single-arm, Open-label Study of Atezolizumab and Derazantinib for Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab EfficacyStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE TrialStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase IIA Trial of Short-term Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/Gastroesophageal-junction (GEJ) AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based TherapyStatus: Completed, Estimated PCD: 2022-01-13
Clinical trial
IMMULAB - A Phase II Trial of Immunotherapy With Pembrolizumab in Combination With Local Ablation for Patients With Early Stage Hepatocellular Carcinoma (HCC)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Nivolumab With Chemotherapy in Pleural Mesothelioma After SurgeryStatus: Active (not recruiting), Estimated PCD: 2024-12-01